Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALKS 7290 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Level 1 | EXPERIMENTAL | - |
| Dose Level 2 | EXPERIMENTAL | - |
| Dose Level 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Placebo capsule taken daily |
| Name | Type | Description |
|---|---|---|
| ALKS 7290 | DRUG | ALKS 7290 tablets taken daily, orally, for 4 weeks |
| Placebo | DRUG | Placebo capsule taken daily |
Inclusion Criteria: * Meets the Diagnostic and Statistical Manual of Mental Disorders -5 criteria for ADHD, as confirmed by the Mini-International Neuropsychiatric Interview (MINI) for ADHD Studies 7.0.2. * Is otherwise healthy as determined by medical evaluation, including medical history, physica...
ALKS 7290 is an investigational small molecule being developed for the treatment of attention deficit disorder with hyperactivity (ADHD) in adults. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ALKS 7290 targets the orexin 2 receptor, a type of receptor involved in regulating arousal, wakefulness, and attention. By acting on this receptor, the drug is being studied for its potential effects on symptoms of ADHD.
ALKS 7290 is being developed by Alkermes plc, a biopharmaceutical company listed on the NASDAQ under the ticker symbol ALKS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ALKS 7290 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is designed to assess its safety and efficacy compared with placebo in adults with ADHD.
ALKS 7290 is being studied in a Phase 2 clinical trial with the identifier NCT07755410. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of ALKS 7290 in adult participants with ADHD. The trial is currently recruiting participants in the United States and aims to enroll 312 individuals aged 18 years and older.